Faron Pharmaceuticals Oy (LON:FARN) Sets New 12-Month Low – Here’s What Happened

Faron Pharmaceuticals Oy (LON:FARN)’s share price reached a new 52-week low on Monday . The stock traded as low as GBX 41 and last traded at GBX 43.77, with a volume of 145928 shares trading hands. The stock had previously closed at GBX 43.

Faron Pharmaceuticals Oy Stock Down 1.6%

The business’s 50 day simple moving average is GBX 96.44 and its 200-day simple moving average is GBX 153.38. The company has a market cap of £49.01 million, a price-to-earnings ratio of -1.57 and a beta of 1.09. The company has a debt-to-equity ratio of -133.35, a quick ratio of 1.09 and a current ratio of 0.84.

Insider Activity

In related news, insider Jurriaan Dekkers sold 4,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. Corporate insiders own 3.94% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.